Xylo Technologies (Xylo Technologies) Total Current Assets : $31.67 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Xylo Technologies Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Xylo Technologies's total current assets for the quarter that ended in Dec. 2023 was $31.67 Mil.

Xylo Technologies Total Current Assets Historical Data

The historical data trend for Xylo Technologies's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xylo Technologies Total Current Assets Chart

Xylo Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

8.28

24.05

31.65

52.26

31.67

Xylo Technologies Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Current Assets	Get a 7-Day Free Trial															31.65	45.96	52.26	46.54	31.67

Xylo Technologies Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Xylo Technologies's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	12.536	+	15.643	+	2.386	+	1.106
	=	31.67

Xylo Technologies's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	12.536	+	15.643	+	2.386	+	1.106
	=	31.67

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Xylo Technologies (NAS:XYLO) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Xylo Technologies's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	12.536	-	31.461	+	0.75 * 12.32	+	0.5 * 2.386
=	-8.49

Xylo Technologies Total Current Assets Related Terms

Thank you for viewing the detailed overview of Xylo Technologies's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Xylo Technologies (Xylo Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xylo Technologies Ltd (NAS:XYLO) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

2QM0:Germany

Address

10 Hanechoshet Street, 4th Floor, Tel Aviv, ISR, 6971072

Website

https://www.medigus.com

Medigus Ltd is an Israel-based medical device company. It is engaged in the development, manufacturing, and marketing of surgical endostaplers and direct vision systems for minimally invasive medical procedures. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incisionless treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company also develops a range of micro video cameras under the micro ScoutCam portfolio of products. It operates in five segments: Medical, E-Commerce, Online, Electric Vehicles, and Corporate. The company's geographical segments include the United States, United Kingdom, Germany, Israel, China, and Others.